Ra Pharmaceuticals, Inc. announced that data from its Phase 2 clinical trial of zilucoplan for the treatment of generalized myasthenia gravis have been selected for an Emerging Science dual oral and poster presentation at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, PA, from May 4 to 10, 2019. The presentation will feature data from the Phase 2, randomized, double-blind, placebo-controlled clinical trial, as well as data from the open-label, long-term extension study.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.